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Cloning of a novel gene in the human kidney homologous to rat
munc13s: Its potential role in diabetic nephropathy. Glomerular mesan-
gial cells (MC) are believed to play a pivotal role in development of
diabetic nephropathy. We employed differential display reverse transcrip-
tion polymerase chain reaction (DDRT-PCR) comparing human MC
grown under 25 mM and 5.5 mM D-glucose and osmolarity control as a first
step to identify possible candidate genes regulated by hyperglycemia. This
strategy resulted in cloning of a novel gene in human MC, human munc13
(hmunc13), a human homologue of rat munc13s with the N-terminal
segment similar to munc13-1 and the C-terminal segment more similar to
munc13-2. Hmunc13 is also expressed in human kidney cortical epithelial
cells. By using relative RT-PCR and Northern blot, we have confirmed
that expression of hmunc13 in MC is up-regulated by high D-glucose
treatment. Together with previous reports that munc13s binds to diacyl-
glycerol (DAG) and that hyperglycemia increases DAG levels, these
findings point to a potential role of hmunc13 in mediating some of the
acute and chronic changes in MC produced by exposure to hyperglycemia.
Mesangial cells (MC) are believed to play a major role in the
development of diabetic glomerulopathy. Their main extracellular
matrix (ECM) product, collagen IV, is a predominant constituent
of the expanded mesangium, found in diabetic glomerulosclerosis
[1, 2]. Although a number of different cellular metabolic pathways
are known to be altered by exposure to elevated concentrations of
glucose [2, 3], diacylglycerol (DAG) induced protein kinase C
(PKC) activation (especially its b isoform) is probably the most
important [2, 4–6]. Especially persuasive is the evidence that PKC
inhibition reverses many of the acute and chronic effects of
hyperglycemia on MC by blocking DAG binding to PKC [6].
However, whether PKC activation is the dominant dysfunction in
diabetic glomerulopathy still remains to be determined. Also
unknown is whether other signaling pathways stimulated by
hyperglycemia are capable of interacting with and modifying
DAG induced PKC activation.
To investigate the pathophysiology of diabetic glomeruloscle-
rosis, we adopted a strategy utilizing differential display reverse
transcription polymerase chain reaction (DDPT-PCR) to identify
candidate genes differentially expressed in human MC exposed to
high D-glucose conditions, compared to controls.
Using this screening procedure, we obtained a PCR product
95% identical in sequence to rat munc13-2 [7]. Munc13s are a
class of proteins with so far poorly defined function. However,
unc-13, a Caenorhabditis elegans homologue, has been implicated
in neurotransmitter release [7, 8]. The cysteine rich C1 domain of
unc-13, in the presence of calcium, binds specifically to phorbol
ester and DAG. Its binding capacity and specificity are similar to
those of PKC [8–10]. Based on the accumulated structural
information, it is likely that unc-13 and its mammalian homo-
logues serve as a DAG-activated alternative signaling pathway [7,
10, 11] along with PKC [12–15] and N-chimaerin [15, 16].
In a recent report, rat mun13-1 was shown to interact directly
with syntaxin and bind to synaptobrevin and SNAP25—proteins
involved in vesicle trafficking and neurotransmitter release [17].
Interestingly, syntaxins 2, 3 and 4 are expressed in Madin-Darby
canine kidney cells [18]. The presence in MC of a gene homolo-
gous to rat munc13 previously believed to be localized exclusively
in the brain [7] was somewhat unexpected. In addition the fact
that munc13s has been implicated in cell signaling and in partic-
ular in neurotransmission and exocytosis raised the possibility that
this gene was a potentially interesting “target” for regulation by
glucose. For these reasons we embarked on a project to clone the
full length cDNA of human renal homologue of munc13s and
investigate its regulation by glucose.
Using the sequence information derived from DDRT-PCR, we
successfully cloned the human homologue of munc13s from a
human kidney cDNA library. This novel gene is a differentially
spliced isoform with partial identity to both munc13-1 and
munc13-2. We have named it human munc13 (hmunc13) (Gen-
Bank accession # AF020202). Using RT-PCR, we have demon-
strated that it is expressed in human cortical epithelial as well as
MC. Of great interest is the fact that munc13 expression in MC is
up-regulated by high D-glucose treatment. This finding was con-
firmed by relative RT-PCR and Northern blot analysis. In summary,
hmunc13 is expressed in human kidney MC and up-regulated by high
D-glucose treatment. Consequently, DAG induced hmunc13 activa-
tion becomes a potential new mechanism contributing to the MC
changes observed under hyperglycemic conditions.
METHODS
Materials
MC basal culture medium (MsBM) and renal epithelial basal
medium (REBM) were purchased from Clonetic (San Diego, CA,
USA). Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s
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medium (DMEM), penicillin, streptomycin, human kidney cDNA
library, SuperScript II RNase H2 reverse transcriptase, dNTP, E.
coli RNase H, Taq DNA polymerase, Genetrapper cDNA Positive
Selection System, 100 bp DNA size markers, Klenow Fragment,
m7G(59)ppp(59)G RNA capping analog, ElectroMAX DH10B
cells and restriction enzymes were obtained from Gibco BRL
(Burlington, ON, Canada). DNase I and T7Sequence kit were
purchased from Pharmacia Biotech (Uppsala, Sweden). TA clon-
ing kit was from Invitrogen (San Diego, CA, USA). RNeasy total
RNA preparation kit, QIAshredder and QIAquick Gel Extraction
kit were purchased from Qiagen (Chatsworth CA, USA). SP6
RNA polymerase, human cyclophilin template, 18S rRNA prim-
ers and competimers were from Ambion (Austin, TX, USA). Vent
DNA polymerase was obtained from New England Biolab, Inc.
(Beverly, MA, USA). Rapid hybridization buffer and a-[32P]-
dATP (specific activity 800 Ci/mmol) were purchased from Am-
ersham (Arlington Heights, IL, USA). [35S]-Methionine (specific
activity, 1000 Ci/mmol) was from NEN Life Science Products
(Boston, MA, USA). Duralon-UV membranes was purchased
from Stratagene (La Jolla, CA, USA). Six percent denatured
polyacrylamide solution was purchased from National Diagnostics
(Somerville, NJ, USA). Oligonucleotides were synthesized by
Gibco BRL. X-ray film was from Kodak (Rochester, NY, USA).
Flexi-rabbit reticulocyte lysate system and canine pancreatic mi-
crosomal membranes were purchased from Promega (Madison,
WI, USA). Other chemicals with cell culture or molecular biology
grade were obtained from local suppliers.
Cell culture
Primary cultures of human kidney MC and cortical epithelial
cells were purchased from Clonetic. Human MC were plated onto
25 cm2 culture flasks and incubated in MsBM containing 5.5 mM
D-glucose with 100 U/ml penicillin, 100 mg/ml streptomycin and
5% FBS. Cells were subcultured at 80 to 90% confluence. Cortical
epithelial cells were grown in REBM supplement with 100 U/ml
penicillin and 100 mg/ml streptomycin. Rat renal MC were
prepared and cultured as previously described [19, 20].
Protocol for studying the effect of high glucose concentration
on human kidney mesangial cells
Human MC between passages 5 to 9 were used in this study.
Three parallel experimental conditions were employed: 25 mM
D-glucose (high D-glucose), 5.5 mM D-glucose (normal glucose
control) and 25 mM L-glucose (osmolarity control). The details
are as follows: for high glucose treatment, subconfluent MC were
growth-arrested in MsBM 1 0.5% FBS overnight and exposed to
5.5 mM or 25 mM D-glucose for three days with one change of
medium on the second day. In parallel, L-glucose at the final
concentration of 19.5 mM was added to the culture medium to
serve as an osmolarity control. To investigate if any dose-depen-
dency of hmunc13 expression by D-glucose treatment, in North-
ern blot studies, we analyzed two more sets of human MC
cultured in 15 mM D-glucose or 5.5 mM D-glucose 1 9.5 mM
L-glucose for three days. We have found that changing the
medium every two days at 25 mM D-glucose is enough to maintain
physiological pH in the medium (pH 7.4) (data not shown). At the
end of the experimental treatment period, total RNA of the cells
was prepared.
Isolation of total RNA
Total RNA from human MC and cortical epithelial cells as well
as rat MC was prepared using an RNeasy total RNA preparation
kit according to manufacturer’s instructions. Cell lysates were
prepared following homogenization using a QIAshredder.
DDRT-PCR
DDRT-PCR was performed by modified methods published by
Liang and Pardee [21] and Sokolov and Prockop [22]. Total RNA
from human kidney MC was incubated with DNase I to remove
any contaminating genomic DNA prior to first strand DNA
synthesis. Reverse transcription (RT) was carried out by incubat-
ing a 20 ml reaction mixture containing 1 mg total RNA, 100 ng
fully degenerate hexamer, 500 mM each of dATP, dGTP, dCTP
and dTTP and 200 units of reverse transcriptase (SuperScript II
RNase H2) together with the buffer provided by the manufac-
turer. The reaction mixture was incubated at 42°C for 50 minutes.
The reaction was terminated by heating at 70°C for 15 minutes. E.
coli RNase H (2 units) was then added to the reaction mixture
followed by incubation at 37°C for a further 20 minutes to remove
RNA complementary to the cDNA. Demonstration that the RNA
was free of genomic DNA was confirmed using a pair of GAPDH
specific primers (59-ACCACAGTCCATGCCATCAC-39 and 59-
GTCCACCACCCTGTTGCTGTA-39) to obtain PCR products
before and after RT. We found that there was no amplification in
the absence of RT but a strong band was present in the presence
of RT (data not shown). PCR was carried out using two 10-mer
oligonucleotides, 59-CAAGCGAGGT-39 and 59-GTGGAAGC
GT-39. In a total of 12.5 ml, the reaction mixture contained 1 ml of
RNA with RT, 100 mM of each of dNTP, 4 mM of oligonucleotides,
1.5 mM of MgCl2, 0.1 mCi/ml of a-[
32P]-dATP and 1.25 unit of
Taq DNA polymerase. PCR was carried out using a Perkin
Elemer PCR System 2400 (Perkin Elemer, Foster City, CA, USA)
starting at 94°C for one minute, 34°C for one minute and 72°C for
one minute for 45 cycles. The resulting PCR products were
subjected to 6% denatured polyacrylamide gel electrophoresis
(PAGE) using radiolabeled 100 bp ladder as size markers. The
gels were then dried and exposed to x-ray film overnight. Bands
which showed clear cut differences in high (25 mM) compared to
low (5.5 mM) D-glucose or the osmolarity control (25 mM L-
glucose) were excised by aligning the film with the gel followed by
elution overnight in 10 mM Tris-EDTA buffer (pH 8.0). Eluted
DNA was purified and subjected to a second run of PCR by the
same pair of 10-mer oligonucleotides under the same experimen-
tal conditions without radiolabeled dATP. Fresh PCR products
from this last step were cloned into pCR2.1 using a TA cloning kit.
Clones with inserts were sequenced by using a T7Sequencing kit
with T7 promoter as a primer according to the manufacturer’s
instructions. The resulting DNA sequences were compared to the
GenBank database using BLAST search.
Library screening
Screening of Superscript human kidney cDNA library was
achieved using a Genetrapper cDNA Positive Selection System.
Captured cDNAs were transformed to ElectroMAX DH10B
competent cells by electroporation with an electroporation system
(BTX Inc., San Diego, CA, USA) setting at 16.6 kV/cm. We first
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used an oligonucleotide (59-GTGGTGATGAACACAATG-
GAGAGG-39) originally derived from sequence information fol-
lowing DDRT-PCR to capture a partial length of hmunc13.
According to this sequence information, we then designed an-
other oligonucleotide (59- TCCTGTTTGGGAGGAGAAGT-
TCC-39) closer to the 59 end of the sequence to capture a full
length clone. The resulting clone (pCMVzSPORThmunc13) was
sequenced from both strands using standard techniques described
above. The primers were SP6, T7 promoters or synthetic oligonu-
cleotides derived from the sequence information. Alignment and
analysis of sequences was performed with Genework 2.5.1 (Ox-
ford Molecular Group, Campbell, CA, USA) using a Macintosh
computer. Comparisons of similarity were performed using the
Gapped BLAST search from GenBank.
Relative RT-PCR and RT-PCR
For relative RT-PCR, RT products previously described were
subjected to PCR for 30 cycles using a pair of primers (59-
GGAGCAAATCAATGCCTTGG-39 and 59-TCGGATCCAAT-
GTGCTCTGG-39) specific for hmunc13, amplifying a 671 bp
fragment. 18S rRNA was chosen as a housekeeping gene by using
18S rRNA primers and 18S rRNA competimers with a ratio of
1:2. These primers amplify a 488 bp fragment. Resulting PCR
products were subjected to 1.2% agarose gel electrophoresis.
To determine munc13 expression in epithelial and rat MC, we
employed RT-PCR with a pair of primers (59-GA(T)GTC(A)CT-
GAAGGAGCTCTGG-39 and 59-AGGACA(T)GCACACT-
GCTTTGG-39) targeted to hmunc13 and rat munc13-2 both of
which yield a 193 bp fragment. RT were performed post DNase I
treatment on total RNA extracted from these cells as described
above.
Northern blot
Total RNA (15 mg) extracted from human kidney MC was
subjected to 1% denatured formaldehyde agarose gel electro-
phoresis as described [23] then transferred to Duralon-UV mem-
branes overnight and exposed to UV light for cross linking. An
32P-radiolabeled probe of hmunc13 were generated from a PCR
fragment derived from pCMVzSPORThmunc13 (4095-4288) with
a-[32P]-dATP using a Klenow Fragment and random hexamers.
Membranes were pre-incubated with rapid hybridization buffer at
65°C for 15 minutes and then incubated with radiolabeled probes
at 65°C for two hours. After removal of the radiolabeled probes,
membranes were washed first in 2 3 SSPE (1 3 SSPE contains
150 mM NaCl, 20 mM NaH2PO4 and 1 mM EDTA, pH 7.4) with
0.1% SDS at room temperature for at least 20 minutes then twice
with 0.1 3 SSPE with 0.1% SDS at 65°C for 30 minutes each.
After exposure to the Phosphor screen (Molecular Dynamics,
Sunnyvale, CA, USA), the blots with hmunc13 probe were
stripped with a boiling solution of 0.1 3 SSPE with 0.1% SDS.
The stripped membranes were reprobed with a 32P-labeled human
cyclophilin template using the labeling method described above
expect unlabeled dATP in a final concentration of 4 mM was added
to the reaction. Radioactivity of each band in digital images was
analyzed on a PC using ImageQuant 4.0 (Molecular Dynamic).
In vitro translation
In vitro translation was performed according to previously
published method [24]. Plasmid with hmunc13 cDNA (pCMVz
SPORThmunc13) was linearlized with HindIII. Linearlized DNA
(1 mg) was transcribed with SP6 RNA polymerase and
m7G(59)ppp(59)G RNA capping analog. Capped cRNA was ex-
tracted using an RNeasy total RNA preparation kit. Eluted cRNA
was precipitated and resuspended in 5 ml diethylpyrocarbonated-
treated water. In the presence of 1 ml of this cRNA product, in
vitro translation was achieved using a Flexi rabbit reticulocyte
lysate system according to the method provided by supplier. Two
negative controls were run to ensure in vitro translation products
were derived from in vitro transcript cRNA. In one reaction,
cRNA was replace with 1 ml of H2O and incubated at the same
conditions. In the other reaction, the in vitro transcription cRNA
product was incubated with 2 units of RNase H at room temper-
ature for 15 minutes and 1 ml of this product was replaced with
cRNA in the in vitro translation reaction and incubated at the
same conditions. Translation products were detected by incorpo-
rating 1 mCi/ml of [35S] methionine in the reaction mixture. To
determine co-translational processing, 1.5 equivalent of canine
pancreatic microsomal membranes was added to 10 ml of in vitro
translation reaction. The resulting reaction was centrifuged at
16,000 g for 15 minutes to pellet microsomes. in vitro translation
products were subjected to 8% PAGE. The gel was stained with
Commassie brilliant blue then destained. The stained gel was then
dried and exposed to x-ray film.
Statistical analysis
Group differences in densitometry of the Northern blots were
analyzed by Student’s t-test using Systat 5.2.1. (Systat Inc., Evan-
ston, IL, USA) for the Macintosh. Significance level was set at P ,
0.05.
RESULTS
DDRT-PCR
DDRT-PCR carried out on RNA extracts from MC exposed to
high versus low glucose conditions yielded 10 bands which exhib-
ited differences between high glucose treatment and controls
(both normal glucose and osmolarity controls) (data not shown).
After the bands had been cut, reamplified, cloned and sequenced,
the sequences were compared to the GenBank database. Seven of
those cDNA sequences showed no significant similarity to the
reported cDNAs in the GenBank. One has 99% identity to
AEBP1 (residues 943-1247) which is a gene regulating the differ-
entiation of osteoblasts (GenBank accession # D86479), and
another has 90% similarity to residues 377 to 500 of human
endogenous retrovirus type C oncovirus (GenBank accession
# M74509). One of the cDNA sequences had about 95% identity
to a segment (residues 3523-3863) of rat munc13-2 [7]. Since rat
munc13-2 is viewed as having a potential signaling function
particularly in neurotransmission and in addition has not previ-
ously been reported in any tissue outside the brain, we elected to
clone the full gene from human kidney and confirm the nature of
its regulation by high D-glucose. The other nine DDRT-PCR
products await further characterization.
Cloning of hmunc13
As a first step we cloned a partial length cDNA from a
commercial human kidney cDNA library using oligonucleotides
derived from sequence information obtained from DDRT-PCR
comparing cells at 25 mM D-glucose versus 5.5 mM D-glucose and
osmolarity control (Methods). Then, using the sequence of the
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Fig. 1. Protein sequence alignment of hmunc13 (GenBank accession number AF020202) with rat munc13s. (Top) Alignment of all four proteins. Only
a partial (AA 251-2207) of rat munc13-3 is shown. (Bottom) Alignment of the first 100 amino acids at the N-terminal of hmunc13 and rat munc13-1.
Identical residues are boxed. The dotted line above the sequence indicates the C1 domain and continuous lines indicate the C2 domains as proposed
by Brose et al [7].
partial length clone, we designed another oligonucleotide closer
to the 59 end and proceeded to clone a full-length cDNA (6.3 kb,
pCMVzSPORThmunc13), which we have named hmunc13. This
cDNA encodes a protein with a predicted molecular weight of
180.5 kDa. As shown in Figure 1, kidney hmunc13 contains three
C2 domains and one C1 domain. The N-terminal segment of
hmunc13 (residues 1 to 100) is 85% identical to rat munc13-1 (Fig.
1B). The next segment (residues 101 to 391) exhibits considerable
variation in hmunc13 compared to rat munc13s and unc-13 [7].
The C-terminal segment of unc-13s is highly conserved among
human, rat and C. elegans (Fig. 1) [7]. In particular, the protein
segment from residues 392-1591 of hmunc13 is about 93%
identical to rat munc13-2 (residues 766-1985), 79% identical to
munc13-1 (residues 486-1735) and 74% identical to munc13-3
(residues 1000-2207). In summary, the C terminus of renal
hmunc13 has strongest identity to rat munc13-2 whereas the
N-terminal of hmunc13 has strongest identity to rat munc13-1.
High D-glucose concentration up-regulates hmunc13 mRNA
expression in kidney mesangial cells
To confirm the differential expression of hmunc13 under
varying glucose concentrations two independent methods were
employed. In a pilot study, by using ribonuclease protection
assays, we have found that expression of hmunc13 in human MC
treated with 19.5 mM L-glucose 1 5.5 mM D-glucose (osmolarity
control) was not changed (data not shown). Therefore, in the
following experiment, we only compared the difference of
hmunc-13 expression between high D-glucose and high L-glucose
treated MC. We first used relative RT-PCR with 18S rRNA as a
housekeeping gene. As shown in Figure 2A, hmunc13 was up-
regulated in the high-glucose (25 mM) treated MC compared to
osmolarity controls. In a more quantitative way, Northern blot
analysis was carried out on cells grown according to the same
protocol. As revealed by relative RT-PCR, hmunc13 expression
was increased in MC after high D-glucose treatment (Fig. 2B).
Quantitative densitometry analysis revealed 70% increase of
hmunc13 expression after exposure to 25 mM D-glucose treatment
(P , 0.05, N 5 5, Student’s t-test). As shown in Figure 2B,
hmunc13 expression in MC following exposure to 15 mM D-
glucose was also increased relative to osmolarity control, but there
was no statistically significant difference between 15 mM D-
glucose and 25 mM D-glucose treated cells.
Expression of munc13 in epithelial and rat mesangial cells
To determine if munc13 is also expressed in other cell types in
the kidney besides MC and whether it is expressed in the rat MC
as well as human, RT-PCR was performed using a pair of primers
specific for both hmunc13 and rat munc13-2. As shown in
Figure 3, hmunc13 was detected in cultured human kidney cortical
epithelial cells and munc13-2 was also expressed in primary
cultured rat MC. Genomic contamination is unlikely since no
band was observed in the no RT control for the GAPDH
housekeeping gene (Fig. 3).
Hmunc13 is expressed as a 180 kDa protein in vitro and is
possibly membrane associated
Using a cell free in vitro translation system, we have demon-
strated that hmunc13 is expressed as a ;170 kDa protein (Fig. 4).
This is close to the predicted molecular weight (180.5 kDa) from
the cDNA clone. A number of less prominent lower molecular
weight bands is also present following in vitro translation because
of either initiation of translation from internal AUG codons
rather than the first interaction site or a premature termination of
translation. Both no cRNA (Fig. 4) and RNase H treatment (data
not shown) negative controls showed no detectable band. Also
shown in Figure 4 is that in the presence of canine pancreatic
microsomal membranes, a proportion of full length hmunc13
protein is shifted to a higher molecular weight (;180 kDa)
suggesting that it is membrane associated and undergoes co-
translational processing. Only the full-length protein is associated
with the membrane because the partial length in vitro translation
products are not observed in the microsomal pellet (Fig. 4).
DISCUSSION
We have isolated and cloned a gene from human kidney cDNA
library homologous to rat munc13s. Hmunc13 contains one C1
domain and three C2 domains. The N-terminal segment is more
Fig. 2. Expression of hmunc13 in human mesangial cells (MC) cultured
in high D-glucose compares to osmolarity controls as described in the
Methods section. MC were incubated in culture medium containing 15 mM
D-glucose (D[15]), 25 mM D-glucose (D), 5.5 mM D-glucose 1 9.5 mM
L-glucose (L [15]) or 5.5 mM D-glucose 1 19.5 mM L-glucose (L) for three
days after growth-arrested in 0.5% FBS overnight. Increased expression of
hmunc13 after high D-glucose treatment is revealed by relative RT-PCR
(A) and Northern blot analysis (B). All blots are representative of at least
three different experiments using different total RNA preparations.
Fig. 3. Expression of hmunc13 (lanes 7 and 8) or munc13-2 (lane 9) in
human kidney mesangial cells (MC; lane 7), human renal cortical
epithelial cells (lane 8) or rat kidney MC (lane 9). RT-PCR was
performed using a pair of primers for both hmunc13 and rat munc13-2
indicated in the Methods section, which amplified a segment of 193 bp. To
confirm no genomic DNA contamination in the RNA preparation, a pair
of primers for GAPDH generated a 453 fragment were used to PCR no
RT RNA (lanes 1 to 3) and RT products (lanes 4 to 6) of human kidney
MC (lanes 1 and 4), cortical epithelia cells (lanes 2 and 5) and rat MC
(lanes 3 and 6).
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identical to rat munc13-1 and the C-terminal segment is more
identical to rat munc13-2, which contains one C1 and two C2
domains. After further analysis of the hmunc13 nucleotide se-
quence (GenBank accession number AF020202), we found that
another AUG codon (residues 444 to 446) after the first C2
domain contains an optimal Kozak sequence (59-CACCAUGG-
39) [25]. It is possible that hmunc13 mRNA serves as a bifunc-
tional mRNA [25] that encodes two open reading frames, one for
an isoform with 3 C2 domains (munc13-1) and the other with only
2 C2 domains (munc13-2).
The function of munc13s protein is so far not well defined [7].
However, because mutations of the C. elegans homologues
(unc-13) cause uncoordinated movements [8] and its localization
in the rat brain and synaptic membranes, it has been postulated
that munc13s might participate in signaling events associated with
neurotransmitter release [7, 26]. In a previous report [7], expres-
sion of munc13s was not detected in rat kidney by both Northern
and immunoblot assays leading these authors to conclude that
munc13s is brain specific. The fact that munc13-2 or munc13s are
expressed at low levels in certain cell types might make it difficult
to detect this protein in tissue homogenates. In the present study,
we have demonstrated the presence of munc13 in primary cul-
tured human MC and in a human kidney cDNA library as well as
munc13-2 in rat MC. To our knowledge, this is the first report
describing the existence of munc13s outside the central nervous
system. We have also confirmed that hmunc13 is expressed in the
brain by PCR of a commercial human brain cDNA library (Gibco
BRL) (data not shown).
Our finding that renal hmunc13 is possible membrane associ-
ated is consistent with the observation of others that by immuno-
blotting [7] that rat munc 13-1 is membrane associated. In vitro
translation also indicates co-translational modification of
hmunc13. However, it is unlikely that this initiates N-glycosylation
since addition of a competitive inhibitor of N-glycosylation,
Ac-Asn-Tyr-Thr-NH2 [24], did not shift the band to lower molec-
ular weight (data not shown).
Analysis of the hydropathy plot of hmunc13 by Kyte-Doolittle
analysis indicates that there are a few hydrophobic regions
(residues 603-609, 817-825, 970-977, 1107-1111) with K-D values
from 139 to 172. However, these are not typical transmembrane
segments. It is possible that the full-length protein can fold in such
a way that hydrophobic loops can anchor to the membrane, but
that this such folding is not possible for the partial length protein.
However, to obtain conclusive evidence that renal hmunc13 is
membrane associated will necessitate immunolocalization studies.
This will be possible when a specific antibody to hmunc13
becomes available.
The function of hmunc13 in the kidney is currently under
investigation. It has been shown that a recombinant protein of C1
domain from C. elegans unc-13 has the capacity to bind to phorbol
esters and DAG similar to PKC [8]. Since the C1 domain is highly
identical among C. elegans unc13, rat munc13s and hmunc13 (Fig.
1) [7], it is reasonable to propose that the C1 domain in the
hmunc13 also has the same binding capacity for phorbol esters.
Another class of proteins with C1 domains exhibiting phorbol
ester binding [15], N-chimaerin, has been shown to be a GTPase-
activating protein involved in signal transduction [16]. Taken
together, these data suggest that the munc13s are involved
somehow in cell signaling responding to DAG binding. Recent
reports showing that munc13-1 directly interacts with the N-
terminus of syntaxin [17] and Doc2 [27], proteins that play
important roles in neurotransmitter release, exocytosis, and vesi-
cle docking and fusion [28], further support a role for munc13-1 in
signaling events leading to neurotransmitter release and exocyto-
sis.
Expression of Syntaxin 4 was detected in the rat kidney [29] and
syntaxins 2, 3 and 4 have been found in Madin-Darby canine
kidney (MDCK) cells [18]. It is possible that these syntaxins are
also present in the human kidney. Since hmunc13 is expressed in
both MC and cortical epithelial cells, it would be of interest in
future studies to determine if munc13 interacts with the syntaxins
in these cells known to be involved in vesicle trafficking.
In the present study, we also found that expression of hmunc13
in cultured MC was up-regulated by high-glucose treatment (25
mM D-glucose). However, it seems that even 15 mM D-glucose is
enough to stimulate the over expression of hmunc13 as revealed
by Northern blot. In a pilot in vivo experiment, using in situ
hybridization with a probe specific for rat munc13-2, we have
found that munc13-2 is up-regulated in renal glomerular MC of a
streptozotocin-treated diabetic rat compared to a normal control
(unpublished observation; Y. Song and M. Silverman). There are
numbers of reports indicated that hyperglycemia increases PKC
activity in MC [5, 6, 30]. Furthermore, DAG levels are increased
when cultured MC are exposed to hyperglycemia [2, 6]. Since
munc13s and PKC share similar binding capacities for phorbol
esters and DAG and both PKC and munc13s contain C2 domains,
munc13s might constitute an alternative cascade following DAG
binding. Thus munc13 might be activated in response to hyper-
glycemic induced increases in DAG. Even though munc13s do not
contain a kinase domain and cannot therefore serve as down-
stream regulators by protein phosphorylation [7, 20], nevertheless
it is possible that the munc13s modulate intracellular events
through competitive binding of PKC or by regulation of vesicle
trafficking and exocytosis.
In conclusion, we have cloned a novel isoform of mammalian
munc13s expressed in human kidney. It is detectable in both MC
and epithelial cells. The expression of munc13 is up-regulated by
high D-glucose concentration in cultured kidney MC. This protein
contains a C1 domain with the capacity to bind DAG. Since MC
hmunc13 expression is up-regulated by high D-glucose, this
Fig. 4. In vitro translation of hmunc13. Lane 1 is the no cRNA negative
control. Note that a proportion of the highest molecular weight band (170
kDa) in the absence of microsomal membrane (lane 2) is shifted to higher
molecular weight (180 kDa) in the presence of microsomal membrane
(lane 3). Lane 4 is the supernatant derived from the in vitro translation
reaction with microsomal membranes as detailed in the Methods section.
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protein may be implicated in some of the acute and chronic effects
of hyperglycemia in MC, and possibly contribute to the develop-
ment of diabetic glomerulopathy.
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APPENDIX
Abbreviations used in this article are: DAG, diacylglycerol; DDRT-
PCR, differential display reverse transcription polymerase chain reaction;
DMEM, Dulbecco’s modified Eagle’s medium; ECM, extracellular matrix;
MC, mesangial cells; MsBM, mesangial cell basic culture medium; PAGE,
polyacrylamide gel electrophoresis; PCR, polymerase chain reaction;
PKC, protein kinase C; RT, reverse transcription.
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